scholarly journals Clinical Efficacy and Safety of Buyang Huanwu Decoction for Acute Ischemic Stroke: A Systematic Review and Meta-Analysis of 19 Randomized Controlled Trials

2012 ◽  
Vol 2012 ◽  
pp. 1-10 ◽  
Author(s):  
Chi-zi Hao ◽  
Fan Wu ◽  
Jiangang Shen ◽  
Lin Lu ◽  
Deng-lei Fu ◽  
...  
Keyword(s):  
Systematic Review ◽  
Ischemic Stroke ◽  
Randomized Controlled Trials ◽  
Acute Ischemic Stroke ◽  
Clinical Efficacy ◽  
Meta Analysis ◽  
Controlled Trials ◽  
Efficacy And Safety ◽  
Buyang Huanwu Decoction ◽  
Randomized Controlled

scholarly journals Effect of Buyang Huanwu decoction for the rehabilitation of ischemic stroke patients: a meta-analysis of randomized controlled trials

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Li Gao ◽  
Zhuoran Xiao ◽  
Chunhua Jia ◽  
Wei Wang
Keyword(s):  
Ischemic Stroke ◽  
Randomized Controlled Trials ◽  
Clinical Efficacy ◽  
Meta Analysis ◽  
Controlled Trials ◽  
Efficacy And Safety ◽  
Stroke Patients ◽  
Buyang Huanwu Decoction ◽  
Randomized Controlled ◽  
Clinical Recommendation

Abstract Purpose Buyang Huanwu decoction (BHD) is a widely used traditional Chinese medicine for the rehabilitation of ischemic stroke patients in China, but its clinical efficacy and safety have not been adequately assessed. In this paper, we conducted a systematic review and meta-analysis to evaluate the efficacy and safety of BHD. Methods We searched seven electronic databases from inception to 31 March 2019. The language was limited to Chinese and English. Randomized controlled trials evaluating the efficacy and safety of BHD for the rehabilitation of ischemic stroke patients were included in the meta-analysis. Reviewers independently performed the screening, data extraction, bias assessment, and data analysis. The treatment efficacy was pooled in a meta-analysis using RevMan 5.3 software with a random-effect model. Any disagreement was resolved by discussion among all reviewers. The PRISMA statement was used in the review process. Results A total of 11 studies with 1084 patients were included in the meta-analysis. The results suggested that BHD was superior to other treatments in terms of clinical efficacy in symptoms and daily activities (n = 684, RR = 1.12, 95% CI: 0.99 to 1.27), clinical efficacy in TCM symptoms (n = 280, RR = 1.45, 95% CI: 1.03 to 2.03), National Institute of Health stroke scale (n = 192, MD = 1.66, 95% CI: -1.08 to 4.40), and activities of daily living (n = 200, MD = 8.20, 95% CI: -3.95 to 20.35). Conclusions The results supported the clinical use of BHD for the rehabilitation of ischemic stroke patients. However, the methodological qualities of the included studies were relatively low, and there were limited reports on adverse events. The clinical efficacy and safety of BHD need to be further confirmed by more well-designed and high-quality randomized controlled trials to warrant the clinical recommendation of BHD for the rehabilitation of ischemic stroke patients.

Sign in / Sign up

Export Citation Format

Share Document